Ascelia Pharma AB

Ascelia Pharma AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development. Mangoral is a novel contrast agent for MR-scans in Phase III clinical studies. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com

Links

Ascelia Pharma website

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral®

Tue, May 07, 2019 17:50 CET

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the company has completed constructive discussions with the European Medicines Agency (EMA) regarding the clinical development program for Mangoral® as a contrast agent in patients with focal liver lesions and severe renal impairment. Ascelia Pharma will now finalise preparations for the clinical Phase 3 study and expects to enrol the first patient during the second half of 2019.Mangoral is an oral contrast agent for liver MRI developed to facilitate the visualisation of focal liver lesions, including liver metastases, using

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Links

Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral®

Media